Drug class
Potassium-sparing mineralocorticoid receptor antagonist prodrug; canrenone precursor
Mechanism of action
Canrenoate is converted to canrenone, which antagonises mineralocorticoid (aldosterone) receptors in the distal nephron, increasing sodium and water excretion while reducing potassium excretion.
General use cases
- Treatment of oedema and hyperaldosteronism-related conditions in countries where intravenous or oral canrenoate products are authorised; specific indications and routes are jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
